Systems and methods for safe syringes

By designing a multi-chamber safe injection system, the combination of proximal and distal drug chambers is leveraged to solve the risks of use of existing injection systems and the inaccuracy of drug combinations, and achieve safe and accurate drugs The effect of conveying and reducing metal contact.

CN114632223BActive Publication Date: 2024-11-15CREDENCE MEDSYSTEMS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210078546.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-08-07
Filing Date
2017-11-01
Publication Date
2024-11-15
Estimated Expiration
2037-11-01

AI Technical Summary

Technical Problem

There is a risk of drug spillage/leakage and component breakage during use of existing injection systems. The needle injection configuration has the risk of sharp needle contact or stabbing, and it is difficult to meet the disposable use, safety, automatic disability and anti-stick needles. New World Standards, while the accuracy of component combinations before drug delivery and drug degradation problems caused by metal contact.

Method used

A multi-chamber safe injection system is designed, including proximal and distal stop members, plunger members and needle holders, to move the needle into a protected configuration by manually actuating the plunger, utilizing proximal and distal The side drug chamber is mixed and injected with drug components and reduces drug contact with metal through polymer coating and sealing members.

Benefits of technology

Effectively reduce the risks of user injury and needle contamination, improve the safety and accuracy of drug delivery, meet the requirements of one-time use and automatic disabling, and minimize the contact time between drugs and metals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114632223B_ABST
    Figure CN114632223B_ABST
Patent Text Reader

Abstract

A system for mixing and injecting medicines includes a syringe body, proximal and distal stop members disposed in the syringe body, a plunger member, and a needle hub assembly connected to a distal needle interface of the syringe body. The proximal and distal stop members form a proximal medicine chamber between the two and a distal medicine chamber between the distal stop member and the distal end of the syringe body. The plunger member includes a needle holding feature structure, an energy storage member, and an energy storage member latch member, all of which are disposed inside the plunger. The first and second sizes of the corresponding proximal and distal medicine chambers can be changed by moving the proximal and distal stop members relative to the syringe body. The needle can be at least partially retracted into the plunger when the plunger member is manipulated relative to the syringe body.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with the application date of November 1, 2017, application number 201780080647.1, and name “System and method for safety syringes”. Technical Field

[0002] The present invention generally relates to injection systems, devices and methods for facilitating various levels of control over the infusion of fluids, and more particularly to systems and methods related to safety syringes in the healthcare industry, and more particularly to systems and methods related to multi-chamber safety syringes in healthcare environments. Background Art

[0003] Millions of syringes are consumed every day in the healthcare industry, e.g. Figure 1A The syringe shown in (2) is a common syringe (2) comprising a tubular body (4), a plunger (6) and an injection needle (8). Figure 1B As shown, such a syringe (2) can be used not only to inject fluid into a patient, but also to extract or discharge fluid from or into a container such as a medicine bottle, a drug vial, a bag, or other drug containing system (10). In fact, due to regulatory constraints in some countries such as the United States and concerns about maintaining sterility, after a medicine bottle (10) is used in conjunction with a syringe (2) as shown in the figure in a specific patient's environment, such a medicine bottle can only be used by one patient and must then be discarded, thereby generating a large amount of medical waste due to the bottle and the remaining medical waste, and even causing periodic shortages of certain key drugs. Reference Figure 2A , showing three Luer-type syringes (12), each having a distally configured Luer fitting geometry (14) so ​​that they can be used with other devices having similar mating geometry, such as Figure 2B Luer manifold assembly (16) shown - connection. Figure 2B The Luer Manifold Assembly can be used to administer liquid medications intravenously to a patient with or without the use of an IV bag. Figure 2A The Luer fitting (14) of the syringe may be referred to as a "male" Luer fitting, while Figure 2BThe Luer fitting (18) of the embodiment may be referred to as a "female" Luer fitting; one of the Luer interfaces may be threaded (in which case the configuration may be referred to as a "Luer lock" configuration) so that the two sides may be coupled by relative rotation, which may be combined with a compressive load. In other words, in one Luer lock embodiment, rotation may be used together with compression to engage with threads in the male fitting (14), the threads being configured to engage with a flange on the female fitting (18) and to form a fluid-tight connection between the devices. In another embodiment, a tapered interface connection geometry may be utilized to provide a Luer engagement utilizing compression without the use of threads or rotation (such a configuration may be referred to as a "slip-on" or "tapered" Luer configuration). While such Luer connectors are considered relatively safe for operators, there is a risk of drug spillage / leakage and component breakage during assembly of the Luer connector. On the other hand, the use of a needle injection configuration presents a risk of a sharp needle contacting or stabbing a person or structure, which is undesirable. For this reason, so-called "safety syringes" have been developed.

[0004] An embodiment of a safety syringe (20) is Figure 3 , wherein the tubular shield member (22) is resiliently biased to cover the needle (8) when released from a locked position relative to the syringe body (4). Another embodiment of the safety syringe (24) is shown in Figure 4A-4B For this configuration, after the plunger (6) is fully inserted relative to the syringe body (4), the retractable needle (26) is configured to retract (28, 26) to a safe position within the tubular body (4), such as Figure 4B Such a configuration, which is configured to self-collapse / contract, may be associated with blood splatter / atomization issues, safe storage of preload energy that may fail and activate before desired, loss of precision in a given adequate injection due to residual dead space within the spring compression volume, and / or loss of retraction rate control which may be associated with pain and patient anxiety.

[0005] The increasing number of Figure 5A and 5B The syringe market is further complicated by the demand for prefilled syringe assemblies shown, which typically include a syringe body or "closed drug delivery system" (34), a plunger tip, a plug or stopper (36), and a distal seal or cap (35) that can be assembled on a Luer-type interface. Figure 5A The cap (35) is shown in place; Figure 5BThe cap has been removed to illustrate the Luer interface (14). Liquid medication may be retained in a volume or medication reservoir (40) between the distal seal and the distal end (37) of the plunger tip (36). The plunger tip (36) may comprise a standard butyl rubber material and may be coated, for example, with a biocompatible lubricious coating (e.g., polytetrafluoroethylene ("PTFE")) to promote preferred sealing and relative movement characteristics relative to the associated syringe body structure and materials. Figure 5B The proximal end of the syringe body (34) in the embodiment of the present invention includes a conventional integral syringe flange (38) which is integrally formed with the material of the syringe body (34). The flange (38) is configured to extend radially from the syringe body (34) and can be configured to extend in a full circumference, or around a portion of the circumference of the syringe body (34). Partial flanges are referred to as "gripped flanges", while others are referred to as "full flanges". The flange is used to grasp the syringe with fingers to provide support for pushing the plunger for injection. The syringe body (34) preferably comprises a translucent material, such as glass or a polymer. In order to form a containment volume within the drug chamber or reservoir (40), and to facilitate the discharge of the associated fluid through the needle, a plunger tip (36) can be positioned within the syringe body (34). The syringe body (34) can define a generally cylindrical shape (i.e., such that a plunger tip 36 having a circular cross-sectional shape can establish a seal against the syringe body (34)), or can be configured to have other cross-sectional shapes, such as an elliptical shape.

[0006] Such components are ideal because they can be standardized and precisely produced in batches by a small number of manufacturers in the world who can manage to meet all of the world's ever-changing regulations for filling, packaging and drug / drug interface material selection and component use. However, such simple configurations will not usually meet the new world standards for single-use, safety, automatic disabling and anti-stick needles. Therefore, some suppliers have turned to more "vertical" solutions, such as Figure 5C The solution (41) shown here attempts to meet all, or at least some, of the criteria using one solution; such products may have significant limitations (including those described above) due to the attempt to meet these criteria for many different scenarios. Figure 3-4B some of the limitations mentioned above) and relatively high storage and usage expenses.

[0007] In addition, more and more injectable liquids (e.g., drugs) have the additional requirement that two or more components must be combined to form an injectable composition or solution shortly before delivery to a patient. Although the multiple components can be mixed in a separate open container before the injectable composition is drawn into a syringe, such mixing in an open container and drawing into a syringe may be inaccurate and result in loss of components or injectable compositions. Furthermore, drawing an injectable composition into a syringe may result in unnecessary exposure of the user to an uncapped needle.

[0008] Additionally, more and more injectable fluids (eg, drugs) have a further requirement to minimize the time the injectable fluid is exposed to metal (eg, stainless steel of the needle).

[0009] There is a need for an injection system that overcomes the shortcomings of currently available configurations. In particular, there is a need for an injection system that can be used, for example, with reference to Figures 5A to 5B The multi-chamber safety injection solution described herein has an existing and relatively well-controlled supply chain for conventionally delivered prefilled syringe assemblies. Summary of the invention

[0010] Embodiments relate to injection systems. In particular, embodiments relate to multi-chamber safety injection systems that move a needle into a protected configuration to minimize accidental user injury and contamination from a used needle.

[0011] In one embodiment, a system for mixing and injecting medicines includes a syringe body defining a proximal opening and a distal needle interface at its distal end. The system includes a proximal stop member and a distal stop member disposed in the syringe body, thereby forming a proximal drug chamber between the proximal stop member and the distal stop member and forming a distal drug chamber between the distal stop member and the distal end of the syringe body. The system also includes a plunger member, which defines the interior of the plunger and is configured to be manually manipulated to insert the proximal stop member relative to the syringe body. The plunger member includes a needle holding feature structure disposed inside the plunger, an energy storage member disposed inside the plunger, and an energy storage member latch member disposed inside the plunger. The system also includes a needle hub assembly, which is coupled to the distal needle interface of the syringe body. The needle hub assembly includes a needle having a needle proximal feature structure, a hub, and a needle latch member configured to couple the needle to the hub. The first size and the second size of the corresponding proximal drug chamber and the distal drug chamber can be modified by the movement of the proximal stop member and the distal stop member relative to the syringe body. The needle may be at least partially retracted into the plunger interior upon manipulation of the plunger member relative to the syringe body to transition the energy storage member latching member from a latched state to an unlocked state.

[0012] In another embodiment, a system for mixing drugs and injecting includes a cartridge body, which defines a proximal opening and a distal needle interface at its distal end. The system also includes a proximal stop member and a distal stop member disposed in the cartridge body, thereby forming a proximal drug chamber between the proximal stop member and the distal stop member and a distal drug chamber between the distal stop member and the distal end of the cartridge body. The system also includes a plunger member, which defines a plunger interior and is configured to be manually manipulated to insert the proximal stop member relative to the cartridge body. The plunger member includes a needle holding feature structure disposed inside the plunger, an energy storage member disposed inside the plunger, and an energy storage member latch member disposed inside the plunger. The system also includes a needle hub assembly, which is connected to the distal needle interface of the cartridge body. The needle hub assembly includes a needle having a needle proximal feature structure, a needle hub, and a needle latch member configured to connect the needle to the needle hub. The first and second sizes of the respective proximal and distal medicament chambers can be changed by movement of the proximal and distal stop members relative to the cartridge body. The needle can be at least partially retracted into the plunger interior when the plunger member is manipulated relative to the cartridge body to convert the energy storage member latch member from a latched state to an unlocked state.

[0013] In one or more embodiments, the needle is configured to at least completely pierce the distal stop member to retract into the interior of the plunger. The energy storage member latch member can be interconnected between the inner surface of the plunger member and the needle retention feature structure. The proximal drug chamber and the distal drug chamber can respectively contain a first component and a second component of the drug to be mixed together before injection into the patient.

[0014] In one or more embodiments, the system has: a delivery configuration, wherein the needle proximal feature is disposed in the distal drug chamber; a transfer configuration, wherein the needle proximal feature has at least partially pierced the distal stop member and is located at least partially disposed in the proximal drug chamber; and a mixing configuration, wherein the proximal stop member and the distal stop member contact each other, thereby transferring the first drug component from the proximal drug chamber to the distal drug chamber to mix the first drug component with the second drug component in the distal drug chamber. The needle may include a distal opening, an intermediate opening disposed in the distal drug chamber when the system is in the delivery, transfer, and mixing configurations, and a proximal opening disposed in the proximal drug chamber when the system is in the delivery and transfer configurations.

[0015] In one or more embodiments, the needle further comprises a plurality of proximal openings, the proximal opening being one of the plurality of proximal openings. When the system is in the delivery and transfer configuration, at least some of the proximal openings may be disposed in the proximal medicament chamber, and when the system is in the mixing configuration, the proximal stop member may occlude at least some of the proximal openings. The proximal stop member may comprise a plug configured to occlude at least some of the proximal openings when the system is in the mixing configuration. The length of the plug may be greater than the distance between the most proximal opening of the plurality of proximal openings and the most distal opening of the plurality of proximal openings.

[0016] In one or more embodiments, the syringe or cartridge body includes a position indicator configured to be adjacent to the distal end of the distal stop when the system is in the mixing configuration. The plunger member may include a retaining clip configured to selectively couple to the syringe or cartridge body when the system is in the mixing configuration to prevent proximal movement of the plunger member relative to the syringe or cartridge body. The retaining clip may be configured to generate an audible signal when the retaining clip is selectively coupled to the syringe or cartridge body.

[0017] In one or more embodiments, the proximal and distal stops include respective first and second polymer coatings on respective distal and proximal surfaces thereof, such that the proximal drug chamber is defined by the syringe or cartridge body and the first and second polymer coatings. The distal stop may have a funnel that tapers in a proximal direction, and a space disposed at the tapered proximal end of the funnel.

[0018] In one or more embodiments, the hub comprises a collet and a sleeve. The collet may be configured to removably couple the needle hub assembly to the distal needle interface of the cartridge body when the sleeve is disposed around the collet. The hub may include a sealing member configured to surround an outer surface of the needle and form a fluid seal therearound.

[0019] In one or more embodiments, the system further comprises a transfer tube disposed in the distal drug chamber. When the needle hub assembly is removably coupled to the distal needle hub of the cartridge body, the needle and the transfer tube may be removably connected. The transfer tube may have a reduced diameter portion at its distal end configured to secure the needle thereto.

[0020] In yet another embodiment, a system for injection includes a syringe body defining a proximal opening and a distal needle interface at its distal end. The system also includes a proximal stop member and a distal stop member disposed in the syringe body, thereby forming a drug chamber between the proximal stop member and the distal stop member. The system also includes a plunger member that defines a plunger interior and is configured to be manually manipulated to insert the proximal stop member relative to the syringe body. The plunger member includes a needle retaining feature structure disposed inside the plunger, an energy storage member disposed inside the plunger, and an energy storage member latch member disposed inside the plunger. The system also includes a needle hub assembly that is coupled to the distal needle interface of the syringe body. The needle hub assembly includes a needle having a needle proximal feature structure, a needle hub, and a needle latch member configured to couple the needle to the needle hub. The needle proximal feature structure is configured to pass through the distal stop member into the drug chamber when the system is in an injection configuration. The needle may be at least partially retracted into the plunger interior upon manipulation of the plunger member relative to the syringe body to transition the energy storage member latching member from a latched state to an unlocked state.

[0021] In one or more embodiments, the drug chamber contains a drug that is sensitive to degradation due to contact with the metal material of the needle during storage. The proximal stop member and the distal stop may include respective first and second polymer coatings on respective distal and proximal surfaces thereof, such that the drug chamber is defined by the syringe body and the first and second polymer coatings.

[0022] In one or more embodiments, the system has a delivery configuration in which the needle proximal feature is not disposed in the drug chamber. The needle proximal feature may have pierced the distal stopper and disposed in the drug chamber, thereby providing a drug exit path to inject the drug into the patient when the system is in the injection configuration.

[0023] In one or more embodiments, the needle includes a distal opening, a middle opening disposed in the medicament chamber when the system is in the delivery and injection configuration, and a proximal opening disposed in the medicament chamber when the system is in the injection configuration.

[0024] In yet another embodiment, a method for mixing and injecting a drug into a patient includes providing a system. The system includes a syringe body defining a proximal opening and a distal needle hub at its distal end. The system also includes a proximal stop member and a distal stop member disposed in the syringe body, thereby forming a proximal drug chamber between the proximal stop member and the distal stop member and a distal drug chamber between the distal stop member and the distal end of the syringe body. The system also includes a plunger member defining a plunger interior and configured to be manually manipulated to insert the proximal stop member relative to the syringe body. In addition, the system includes a needle member having a distal needle tip, a drug passage, a plurality of transfer openings, and a proximal end. The method also includes advancing the plunger member so that the proximal end of the needle member pierces the distal stopper to allow a first drug component from the proximal drug chamber to pass through the drug passage and enter the distal drug chamber to allow the first drug component to mix with a second drug component in the distal drug chamber to form a mixed drug.

[0025] In another embodiment, a method for mixing and injecting a drug into a patient includes providing a system. The system includes a cartridge body, the cartridge body defining a proximal opening and a distal needle interface at its distal end. The system also includes a proximal stop member and a distal stop member disposed in the syringe body, thereby forming a proximal drug chamber between the proximal stop member and the distal stop member and a distal drug chamber between the distal stop member and the distal end of the cartridge body. The system also includes a plunger member, the plunger member defining a plunger interior and configured to be manually manipulated to insert the proximal stop member relative to the cartridge body. In addition, the system includes a needle member having a distal needle tip, a drug passage, a plurality of transfer openings, and a proximal end. The method also includes advancing the plunger member so that the proximal end of the needle member pierces the distal stopper to allow a first drug component from the proximal drug chamber to pass through the drug passage and enter the distal drug chamber to allow the first drug component to mix with a second drug component in the distal drug chamber to form a mixed drug.

[0026] In one or more embodiments, the method further comprises advancing the plunger member to inject the mixed drug into the patient. The method may include automatically retracting the distal needle tip into the syringe body when the mixed drug has been injected into the patient.

[0027] In yet another embodiment, a method for injecting a drug into a patient includes providing a system. The system includes a syringe body defining a proximal opening and a distal needle hub at a distal end thereof. The system also includes a proximal stop member and a distal stop member disposed in the syringe body, thereby forming a drug chamber between the proximal stop member and the distal stop member and a distal drug chamber between the distal stop member and the distal end of the syringe body. The system also includes a plunger member defining a plunger interior and configured to be manually manipulated to insert the proximal stop member relative to the syringe body. In addition, the system includes a needle member having a distal needle tip, a drug passage, a plurality of transfer openings, and a proximal end. The method also includes advancing the plunger member so that the proximal end of the needle member pierces the distal stopper to allow drug from the proximal drug chamber to pass through the drug passage and enter the distal drug chamber.

[0028] In one or more embodiments, the method further comprises advancing the plunger member to inject the drug into the patient.The method may include automatically retracting the distal needle tip into the syringe body when the mixed drug has been injected into the patient.

[0029] In yet another embodiment, a system for mixing and injecting medicines includes a syringe body, which defines a proximal opening and a distal needle interface at its distal end. The system also includes a proximal stop member and a distal stop member disposed in the syringe body, thereby forming a proximal drug chamber between the proximal stop member and the distal stop member and a distal drug chamber between the distal stop member and the distal end of the syringe body. The system also includes a plunger member, which defines the interior of the plunger and is configured to be manually manipulated to insert the proximal stop member relative to the syringe body. The plunger member includes a needle holding feature structure disposed inside the plunger, an energy storage member disposed inside the plunger, and an energy storage member latch member disposed inside the plunger. In addition, the system includes a needle seat assembly coupled to the distal needle interface of the syringe body. The needle assembly includes a needle having a needle proximal feature structure, a seat, and a needle latch member configured to couple the needle to the seat. The first size and the second size of the corresponding proximal drug chamber and the distal drug chamber can be modified by the movement of the proximal stop member and the distal stop member relative to the syringe body. The needle is at least partially retractable into the plunger interior upon manipulation of the plunger member relative to the syringe body to transition the energy storage member latch member from a latched state to an unlocked state. The distal medicament chamber contains a partial vacuum.

[0030] In one or more embodiments, the distal stop member includes a proximal door having a closed configuration in which the needle proximal feature structure cannot pass through the proximal door, and an open configuration in which the needle proximal feature structure can pass through the proximal door. The proximal door may include a pair of movable arms operably connected to a pair of spring elements. The pair of spring elements can bias the proximal door in the closed configuration. The needle proximal feature structure may include a proximal shoulder that cannot pass through the proximal door in the closed configuration, but can pass through the proximal door in the open configuration. The needle may include a distal shoulder that cannot pass through the proximal door in the closed configuration, but can pass through the proximal door in the open configuration, and the distal shoulder is distal to the proximal shoulder. The proximal door may include a pair of operable arms that are operably connected to a pair of self-excited hinges.

[0031] In another embodiment, a method for mixing and injecting a drug into a patient includes providing a system. The system includes a syringe body, the syringe body defining a proximal opening and a distal needle hub at its distal end. The system also includes a proximal stop member and a distal stop member disposed in the syringe body, thereby forming a proximal drug chamber between the proximal stop member and the distal stop member and a distal drug chamber between the distal stop member and the distal end of the syringe body. The system also includes a plunger member, the plunger member defining a plunger interior and configured to be manually manipulated to insert the proximal stop member relative to the syringe body. In addition, the system includes a needle member having a distal needle tip, a drug passage, a plurality of transfer openings, and a proximal end. The distal drug chamber contains a partial vacuum. The method also includes advancing the plunger member so that the proximal end of the needle member pierces the distal stop member to allow the partial vacuum in the distal drug chamber to draw a first drug component from the proximal drug chamber through the drug passage and into the distal drug chamber to allow the first drug component to mix with a second drug component in the distal drug chamber to form a mixed drug.

[0032] In one or more embodiments, the method further includes moving the distal stop member distally to shrink the space in the distal drug chamber so that the system can be used for injection without cleaning the system. The method may also include advancing the plunger member to inject the drug into the patient. The method may also include automatically retracting the distal needle tip into the syringe body when the drug has been injected into the patient.

[0033] The foregoing and other embodiments of the invention are described in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The foregoing and other aspects of the embodiments are described in further detail with reference to the accompanying drawings, in which like elements in different drawings are indicated by common reference numerals, and in which:

[0035] Figures 1A-5CVarious aspects of a conventional syringe configuration are shown.

[0036] Figures 6A-7P Various aspects of a syringe-based dual chamber safety injection system are shown, according to various embodiments, wherein the distal needle end / tip may be withdrawn to a protected configuration after use.

[0037] Fig. 8A and 8B A harpoon-shaped coupling interface according to two embodiments is shown, which may be used with a dual chamber safety injection system according to various embodiments.

[0038] Fig.9A and 9B Various aspects of a hybrid configuration latch according to one embodiment that may be used with a dual chamber safety injection system according to various embodiments are shown.

[0039] Fig. 10A and 10B Various aspects of a mix configuration indicator according to one embodiment that may be used with a dual chamber safety injection system according to various embodiments are shown.

[0040] Figures 11A-11E Shown in increased detail Figure 6A-10B Various aspects of the dual chamber safety injection system are shown to illustrate various aspects of the system.

[0041] Figures 12A-12D Various aspects of a distal stopper bushing according to one embodiment that may be used with a dual chamber safety injection system according to various embodiments are shown.

[0042] Figures 12E-12F Various aspects of a guide tray according to one embodiment that may be used with a dual chamber safety injection system according to various embodiments are shown.

[0043] Figures 13A-13C Various aspects of a proximal stopper thread according to one embodiment that may be used with a dual chamber safety injection system according to various embodiments are shown.

[0044] Figures 14A-16H Various aspects of a cartridge-based dual chamber safety injection system according to various embodiments are shown, wherein the distal needle end / tip can be withdrawn into a protected configuration after use.

[0045] Figures 17A-18G Various aspects of a dual chamber safety injection system configured with a user-connectable needle employing a Luer-type coupling are shown according to various embodiments.

[0046] Figures 19A-19DA dual chamber drug mixing and delivery system for delivering drugs to a patient via an IV port or other delivery method that does not involve injection into the patient is shown.

[0047] Figures 20A-20D A safety injection system for storing and delivering medications that are sensitive to contact with stainless steel is shown according to one embodiment.

[0048] Figures 21A-21D A needle locking mechanism using an adjustable force to unlock the needle is shown.

[0049] Figures 22A-22D One embodiment of the internal mechanism of a safety injection system for storing and delivering medications that are sensitive to contact with stainless steel is shown.

[0050] Figure 23-34 Various aspects of a vacuum-assisted dual chamber safety injection system according to various embodiments are shown, wherein the distal needle end / tip can be withdrawn into a protected configuration after use, including in Fig.25 , 26 and 34 for use therein.

[0051] In order to better understand how to obtain the above and other advantages and purposes of various embodiments, a more detailed description of the embodiments is provided with reference to the accompanying drawings. It should be noted that the drawings are not drawn to scale, and elements of similar structure or function are always represented by the same reference numerals. It should be understood that these drawings only depict certain illustrated embodiments and therefore should not be considered to limit the scope of the embodiments. DETAILED DESCRIPTION

[0052] Exemplary Dual Chamber Safety Syringe System

[0053] refer to Figure 6A-6B, showing a perspective view and a longitudinal cross-sectional view of a dual-chamber safety injection system, the safety injection system having a conventional off-the-shelf pre-filled syringe body (34), wherein conventional proximal stop members and distal stop members (32, 36) are provided. The proximal stop members and distal stop members (32, 36) together with the syringe body (34) define a proximal drug chamber and a distal drug chamber (40, 42). The proximal stop members and distal stop members (36, 37) block the proximal and distal ends of the proximal drug chamber (40). The distal stop member (36) blocks the proximal end of the distal drug chamber (42). A needle coupling assembly (606) is provided at the distal end of the distal drug chamber (42), wherein a needle cover member (63) for storage is installed. The dual chamber safety injection system controls the transfer of a first drug component from a proximal drug chamber (40) to a distal drug chamber (42) and the exit of a mixed / combined drug from the distal drug chamber (42) to the distal side after a user successively inserts a plunger assembly at different degrees relative to a syringe body (34). The plunger assembly includes a proximal stop member (32), a plunger housing member (69) and a plunger manipulation interface (128). The first drug component located in the proximal drug chamber (40) can be a liquid, such as an aqueous or oily drug solution, a gel, or the first drug component can be a diluent for mixing with a second drug component in the distal drug chamber (42). The second drug component in the distal drug chamber (42) can be a drug in a dry form, such as a powder, microspheres, an emulsion, a lyophilized or freeze-dried drug, or a cake-like solid drug. The second drug component in the distal drug chamber (42) can also be a liquid mixed with the first drug component from the proximal drug chamber (40).

[0054] The dual chamber safety injection system has a post-type needle configuration, wherein when presented to the user, it includes a needle coupling assembly (606), a needle distal end / tip (48), a needle coupling structure (83, see e.g. Fig. 6E ) and the needle proximal end (50) of the needle assembly is installed in place ready for injection after removal of the needle cover member (63), which may include a resilient sealing material on its inner surface to interface with the needle distal end (48) or the distal housing portion (610) during storage. Alternatively, the needle cover member (63) may include a vent (not shown) for allowing pressure generated by the transfer and mixing of the drug components to escape from the interior of the syringe body (34) while preventing contaminants from entering the syringe body (34). Although the post needle is depicted as being installed in place, the post needle can be removably coupled to the syringe body (34) using a Luer interface (not shown), with the proximal end (50) of the needle member extending through the Luer interface and into the distal drug chamber (42). Figure 6A-22D In the illustrated embodiment, the majority of the safety needle retraction hardware is located within the plunger housing.

[0055] Reference Figure 6C and 6D , upon initial assembly (i.e., in a factory or processing facility - rather than in the field as in a "post needle" configuration), the proximal housing assembly (608) is configured to snap fit (i.e., using a retaining ring element 604 that includes or is coupled to the proximal housing assembly) onto a slightly recessed radial portion (602) of the syringe body that is formed in the syringe body when the syringe body is manufactured.

[0056] Reference Fig. 6E and 6F The needle spine assembly (76) includes an injection member having a distal needle end (48) and a needle proximal end (50) coupled to a needle coupling structure (83). The needle coupling structure (83) is configured to have a necked or radially reduced portion (111) configured to engage with a latch member (612) and a movable block member (614) so ​​that the needle distal end (48), the needle coupling structure (83) and the needle proximal end (50) remain fixed in place relative to the syringe body (34) during injection, but are not movable when the plunger assembly is relative to the small diameter flange (33 - see e.g. Figure 7N ) after full insertion (i.e., after the drug that may be contained in the distal drug chamber 42 of the syringe body 34 is completely or nearly completely expelled), the movable block member (614) is advanced relative to the distal advancement housing portion (610) so that the plurality (two are shown) of the cantilevered latch members (616) of the latch member (612) are pushed open by the movable block member (614). In particular, the needle spine assembly (76) is urged distally by the full advancement of the plunger assembly, thereby advancing the movable block member (614) to move the cantilevered latch members (616). Moving the cantilevered latch members (616) allows the needle distal end (48), the connecting member (83), and the proximal end (50) to retract through their couplings, thereby safely placing the needle distal end (48) within the plunger housing member (69). Alternatively, the needle distal end (48) can be retracted to a position below the outer surface of the distal housing portion (610) to safely isolate the sharp point from the user. In other words, the cantilevered latch members (616) maintain the position of the needle distal end (48) during injection and during needle / syringe assembly until they are pushed away by the movable block member (614) when the plunger is fully inserted, after which the needle is free to automatically withdraw when triggered by further (toward) distal movement of the needle spine assembly (76), as described in U.S. Patent Application Serial Nos. 14 / 696,342 and 62 / 416,102, which have been previously incorporated herein by reference.

[0057] In one embodiment, the plunger assembly includes a coupling member that forms a gap in the plunger assembly that allows the plunger operating interface to continue to move distally after the distal stop member has reached the distal end of the syringe body to expel substantially all of the mixed drug from the syringe body. In this embodiment, the plunger operating interface is pushed distally a short distance after complete injection to collapse the coupling member and the gap, release the cantilevered latch member, couple the needle spine assembly to the energy storage member, and release the energy storage member to retract the coupled needle spine assembly at least into the syringe body. This embodiment is described in U.S. Patent Application Serial No. 62 / 416,102, which has been incorporated herein by reference.

[0058] Fig. 6E Various aspects of the needle spine assembly (76) are shown, including elements of the needle assembly without the needle coupling assembly (606). The distal portion (48) of the needle spine assembly (76) includes a sharp hypodermic needle tip formed on the injection member (78). Figure 6G and 6H As shown, the needle proximal end (50) also includes a sharp tip (86) formed in a connecting member forming the distal portion. A generally hollow connecting member (83) connects the connecting member to the tubular injection member (78). The injection member (78), the sharp tip (86) on the needle proximal end (50) and the hollow connecting member (83) can be held together by interference fit, welding and / or adhesives. In the illustrated embodiment, the most proximal end (84) of the needle proximal end (50) includes a "harpoon" type geometry that is configured to penetrate and remain on a compliant member that can be engaged therewith, as described in more detail below, for withdrawing the needle spine assembly (76) into the plunger housing member (69). For example, the needle proximal end (50) can be formed from a thin metal sheet component using laser cutting, etching, stamping and / or machining techniques. Other aspects of the needle spine assembly (76), such as the flow path therethrough and the flow blocking portion at least in Figure 6M-6O is shown in and described below.

[0059] Figure 6P A detailed cross-sectional view of the needle coupling assembly (606) snapped onto the syringe body (34) is shown. Figure 6I-6L A partial perspective wireframe diagram is shown to more directly visualize latch member (612) and cantilever latch member (616) relative to needle portion (48, 83, 50, 111). The function of latch member (612) and cantilever latch member (616) in needle retraction is described in U.S. Patent Application Serial Nos. 14 / 696,342 and 62 / 416,102, which have been previously incorporated herein by reference.

[0060] Figure 6PAlso shown is a distal seal (620) configured to provide a seal between a distal drug chamber (42) in a drug container (e.g., syringe body (34)) and an outer surface of the needle spine assembly (76). Preferably, the distal seal (620) is configured to provide a seal around the outside of the needle coupling structure (83). The seal is also configured to provide a seal between the distal drug chamber (42) and an inner surface of the needle coupling assembly (606). Figure 6P Also shown is a snap fit (630) between the distal end of the drug container (eg, syringe body (34)) and the proximal end of the needle coupling assembly (606).

[0061] Back to Figure 6A-6B For example, a dual chamber safety injection system includes a conventional syringe body (34) equipped with a proximal plunger tip and a distal plunger tip (32, 36) configured to be pierced by a needle proximal end (50) at an appropriate time to assist in drug transfer and needle retraction; the proximal plunger tip (32) is coupled to a plunger manipulation interface (128) via a plunger housing member (69) that defines an internal volume occupied by various other parts of the assembly, as described below, which are configured to retract the needle at an appropriate time during use. In the illustrated embodiment, the needle coupling assembly (606) described above is included; other embodiments may include a Luer-type needle assembly coupled to the syringe body (34). The depicted form of syringe body (34) includes a small diameter flange (33) coupled to a conventional integral syringe flange (38) having a geometry that can be manipulated or engaged, for example, between an operator's index and middle fingers while the operator's thumb engages the plunger manipulation interface (128). Fig. 6A and 6B The assembly is shown prior to use, with the needle cover (63) in place to mechanically isolate the needle distal end (48). The needle cover (63) can be removed and the assembly prepared for injection into a patient.

[0062] like Figure 6M As shown, the proximal stop member and the distal stop member (32, 36) together with the syringe body (34) define a proximal drug chamber (40), wherein the dual-chamber safety injection system is in a delivery configuration. In particular, since the distal end of the proximal stop member (32) and the proximal end of the distal stop member (36) are each coated with a lubricating polymer coating (e.g., PTFE), the first polymer coating and the second polymer coating of the proximal stop member and the distal stop member (32, 36) together with the syringe body (34) define a proximal drug chamber (40). The lubricating polymer coating is also used to isolate the rubber of the proximal stop member and the distal stop member (32, 36) from the drug and drug components. The proximal stop member and the distal stop member (32, 36) can be as shown in FIG. Figure 6MAlternatively, the distal stopper may be flipped so that the lubricious coating faces the distal drug chamber (42) so that the second drug component in the distal drug chamber (42) contacts the lubricious coating for storage. Fig.12F The centering guide disc shown and described below remains in place. In an alternative embodiment, the proximal and distal stop members (32, 36) are rubber without a lubricating polymer coating.

[0063] Since the proximal stop member (32) is coupled to the plunger housing member (69) and the plunger operating interface (128), a distally directed force applied to the plunger operating interface (128) will cause the proximal stop member (32) to move in a distal direction relative to the syringe body (34). Since the proximal medicament chamber (40) is pre-filled with a substantially incompressible liquid and since Figure 6M In the delivery configuration shown, there is no path for the incompressible liquid to escape from the proximal drug chamber (40), so distal movement of the proximal stop member (32) causes distal movement of the distal stop member (36).

[0064] like Figure 6N As shown, after the distal stop member (36) has been moved distally relative to the syringe body (34) to place the dual chamber safety injection system in the transfer configuration, the needle proximal end (50) has pierced the distal stop member (36) and partially entered the proximal drug chamber (40). Figure 6M In the transfer configuration shown, the delivery tube (46) portion of the needle proximal end (50) forms a fluid path between the proximal and distal drug chambers (40, 42). The delivery tube (46) includes a plurality of proximal openings (270) and a middle opening (266). The delivery tube (46) is hollow and forms a fluid path between the most proximal opening (270) disposed in the proximal drug chamber (40) and the middle opening (266) disposed in the distal drug chamber (42). Although Figure 6M-6O The delivery conduit (46) shown includes four proximal openings (270) and one intermediate opening (266), but other embodiments may have more or fewer proximal openings and intermediate openings. Increasing the number of proximal openings and intermediate openings increases the positioning tolerance of the delivery tube (46) / needle proximal end (50) relative to the distal stop member (42) while maintaining an open fluid path between the proximal and distal drug chambers (40, 42).

[0065] In the dual chamber safety injection system Figure 6NAfter the transfer configuration shown, as more force is applied to the plunger operating interface (128), the proximal stop member (32) can move proximally relative to the distal stop member (36) because the liquid in the proximal drug chamber (40) can move to the distal drug chamber (42) via the delivery tube (46). When the liquid in the proximal drug chamber (40) is transferred to the distal drug chamber (42), the liquid can mix with the contents of the distal drug chamber (42). Fig. 6A and 6B In the embodiment shown, in the delivery configuration ( Fig. 6A , 6B The liquid in the proximal drug chamber (40) of the distal drug chamber (42) is a first liquid component of the drug. The content of the distal drug chamber (42) is a second component of the drug. The liquid is transferred from the proximal drug chamber (40) to the distal drug chamber (42) to mix the first component and the second component to prepare for injection of the drug.

[0066] like Fig.6O As shown, the continuous force applied to the plunger operating interface (128) from the transfer configuration completes the transfer of liquid from the proximal drug chamber (40) to the distal drug chamber (42) and places the dual chamber safety injection system in a mixing configuration. In the mixing configuration, the first component and the second component are mixed and the drug is ready to be injected into the patient. The mixed drug is disposed in the distal drug chamber (42). The distal movement of the proximal stop member (32) relative to the distal stop member (36) has caused the proximal stop member and the distal stop member (32, 36) to contact and reduce the volume of the proximal drug chamber (40) to substantially zero. Therefore, the continuous force applied to the plunger operating interface (128) causes the proximal stop member and the distal stop member (32, 36) to move together and eject the mixed drug through the distal opening / outlet at the distal end of the delivery tube (46), and eject the mixed drug from the distal drug chamber (42) through the needle into the patient. The delivery tube (46) further comprises an inner cavity plug (268) disposed between the proximal end and the distal end of the inner cavity. During injection of the mixed drug into the patient's body, the inner cavity plug (268) prevents the mixed drug from being forced to flow retrograde through the flow channel.

[0067] refer to Figures 7A-7L , showing various aspects of a configuration designed to facilitate injection of multiple doses of a drug and retraction of the needle into the syringe body, wherein two or more drug components are combined to form an injectable composition or solution shortly before delivery to a patient. In one variation, a liquid first drug component / diluent (252) can be combined with a substantially non-liquid second drug component (254) (e.g., in powder form) of a medicament such as a freeze-dried or lyophilized drug component shortly before injection. Figures 7A-7LThe configuration described relates to a dual chamber configuration, where two or more chambers within the same syringe body (34) are used to carry, mix and inject the injection solution.

[0068] Reference Fig. 7A and 7B The proximal and distal drug chambers (40, 42) are formed between two parts of the interior of the syringe body (34) by a distal stop member (36), so that the distal drug chamber (42) contains an air or gas gap and a non-liquid drug (254); the proximal drug chamber (40) located on the opposite side of the distal stop member (36) contains a liquid diluent (252) contained proximally by the proximal stop member (32). The liquid diluent (252) is a first component of the drug, and the non-liquid drug (254) is a second component of the drug.

[0069] Reference Figure 7C as well as Fig.7D , showing various components of a needle coupling assembly (a so-called "pile-type" needle coupling assembly (606) is shown here, but other needle assemblies may be used as described below, including Luer coupling configurations as well as pile-type configurations). The lug feature (258) is configured to help couple the needle coupling assembly (606) to the needle cover member (63), for example, as Fig. 7A As shown. A small O-ring can be used as a sealing member (260) around the needle shaft, while a larger O-ring can be used as a sealing member (262) at the syringe body (34) / needle coupling assembly (606) interface. Alternatively, the small O-ring (260) and the large O-ring (262) can be combined into a single seal that performs the sealing function of both O-rings. Furthermore, the small O-ring (260) can be used to seal around the needle shaft and can also be used to seal the syringe body (34).

[0070] The needle includes a plurality of (e.g., four) proximal openings / ports (270) configured to allow entry of a liquid diluent for discharge from a more distally located intermediate opening / orifice (266); Figure 6N and 7H Under the conditions described, the lumen plug (268) blocks the needle lumen to form a flow path from the proximal opening (270) to the middle opening (266). The needle also includes a distal opening (264) located on the side of the lumen plug (268) opposite the middle opening (266). The distal opening (264) is fluidically coupled to the needle distal end (48) through the needle to inject liquid into the patient.

[0071] Reference Fig. 7EThe proximal harpoon interface (84) is configured to continuously penetrate the proximal stop member and the distal stop member (32, 36) and to engage with a coupling feature structure in the plunger rod (e.g., a needle retaining feature structure is shown, for example, in Figure 7N and 7P Component 712) is connected. Figure 7F A spiked harpoon coupling interface (85) is shown which is configured to successively pierce the proximal and distal stop members (32, 36) and couple with coupling features in the plunger rod to at least partially retract the needle member into the plunger rod after the patient has been injected.

[0072] Fig. 7A , 7B 7G-7P show a series of actions during the injection process using a dual-chamber safety injection system such as described. Fig. 7A and 7B , the injection assembly is in a stable configuration in which it can be transported or brought to an injection patient care setting; the first drug component / liquid diluent (252) is isolated from the second non-liquid drug component (254), both of which are located on opposite sides of the distal plug member (36) within the syringe body.

[0073] Figure 7G and 7H The initial insertion movement of the plunger assembly (44) is shown, which advances the distal stop member (36) and the proximal stop member (32) together relative to the syringe body (34). Figure 7H When the proximal end (50) of the needle assembly is advanced enough to pierce the distal stop member (36), a fluid path (34) is formed between two previously isolated chambers (40, 42) of the syringe body, so that a liquid first drug component (252) in the proximal drug chamber (40) can flow into at least one proximal opening (270) through the transfer tube (46) and exit the more distal intermediate opening (266) to reach a non-liquid second drug component (254) in the distal drug chamber (42).

[0074] Fig.7I and 7J It is shown that, with further insertion until the stop members (36, 32) are in close proximity to one another, the liquid first drug component / diluent (252) has moved into the distal drug chamber (42) to combine with the non-liquid second drug component (254). Figure 7K and 7L It is shown that, through time and / or manual agitation, the liquid first drug component / diluent (252) and the previously non-liquid second drug component (254) mix to form a mixed drug solution (272).

[0075] In some embodiments, particularly for lyophilized, non-liquid second drug components, a mixed drug solution (272) may be formed with minimal or no agitation or passage of time. In another embodiment, particularly for drugs maintained in suspension or emulsified drugs, vigorous shaking may be required to promote mixing. In the event of vigorous shaking, it is useful for the user to be able to remove their thumb from the plunger operating interface (128). During the transfer of the liquid first drug component (252) from the proximal drug chamber (40) to the distal drug chamber (42), pressure may accumulate in the distal drug chamber (42). This pressure acts on the proximal stop member and the distal stop member (32, 36) to resist movement of the stop members. If the user does not use their thumb to limit the plunger assembly (44), the pressure accumulation may also cause the stop members (32, 36) and the plunger operating interface (128) to move proximally. A mixing configuration latch or "mixing pawl" (in Fig.9A and 9B , and described below) can be used to provide resistance to the movement of the plunger operating interface (128) due to pressure buildup and allow the user to release their thumb from the plunger operating interface (128) for shaking or mixing the medication. The mixing pawl can also provide an audible and / or tactile indication that the transfer of the liquid first drug component (252) has been completed. The distal drug chamber (42) can also include an agitation device that assists in mixing the drug components.

[0076] With the assembly ready for injection of the mixed solution (272), the needle cover member (63) may be removed and the needle may be removed by Figure 7M and 7N The plunger assembly (44) and associated stoppers (36, 32) are shown depressed / inserted to inject the patient using the exposed distal needle end (48). Fig.7O and 7P With the plunger assembly (44) and associated stop members (32, 36) fully depressed / inserted, the sharp needle distal end / tip (48) can be at least partially automatically retracted via the distal stop member and the proximal stop member (36, 32) to a safe position within the syringe body (34), the needle coupling assembly (606), or at least partially retracted into the plunger assembly (44). Automatic retraction of the needle at least partially into the plunger is described in U.S. Patent Application Serial Nos. 14 / 696,342 and 62 / 416,102, which have been previously incorporated herein by reference.

[0077] Existing lyophilization manufacturing processes lyophilize (freeze dry) a solution (e.g., a liquid drug) within a syringe chamber that is sealed with a stopper proximal to the drug. During lyophilization, the distal end of the syringe remains open, exposing the drug to the lyophilization process through the inner diameter ("ID") of the end of the syringe. This existing process typically does not allow the use of conventional glued-on peg needles because the needle must be in place prior to lyophilization due to the glue curing process. Traditional 25G (gauge, standard specifications) to 34G needles have an ID of approximately 0.010" to 0.003". This ID range is typically too small to allow lyophilization of the drug in a reasonable time. Figures 6A-7P The post needle assembly shown uses a Luer taper tip syringe with a distal ID of approximately 0.040" that allows for lyophilization. Figures 6A-7P The stake needle is attached to the syringe via a snap fit after lyophilization has occurred, thereby sealing the drug container and allowing the use of existing lyophilization manufacturing processes.

[0078] Although Figures 6A-7P The illustrated embodiment transfers liquid via a transfer tube (46), but in other dual chamber embodiments, liquid may be transferred via a bypass channel / passageway formed in the syringe body. During syringe formation, a bypass channel may be formed in or near the wall of a glass syringe using a mandrel. The bypass channel may have an opening into the syringe body that may be selectively occluded by proximal and distal stop members to control liquid transfer. These embodiments are described in U.S. Patent Application Serial No. 14 / 696,342, which has been previously incorporated herein by reference.

[0079] A. Exemplary Harpoon Attachment Interface

[0080] Fig. 8A and 8B Two embodiments of dual chamber safety syringe systems having different harpoon coupling interfaces (87, 88) are depicted. Fig. 8A The embodiment shown has an articulated harpoon coupling interface (87). Figure 8B The embodiment shown has a tree-like harpoon-shaped connection interface (88). For clarity, Figure 8B The spring is omitted. These coupling interfaces (87, 88), their corresponding needle retention features (712), and their use for selectively retracting the needle are described in U.S. Patent Application Serial No. 62 / 416,102, which has been previously incorporated herein by reference. Different harpoon-shaped coupling interfaces (87, 88) can be used with Figures 6A-7P Use together as shown in .

[0081] B. Hybrid Configuration Latch

[0082] Fig.9A and 9BDescribes the Figures 6A-8B The hybrid configuration latch (300) on the plunger assembly (44) used in conjunction with the illustrated embodiment. The hybrid configuration latch (300) tapers distally and is biased (e.g., by a spring) to extend radially from the plunger assembly (44). The hybrid configuration latch (300) is configured such that when the dual chamber safety syringe system is in the hybrid configuration (i.e., wherein the proximal stop member and the distal stop member contact each other), the hybrid configuration latch (300) moves distally beyond the detent (302) on the small diameter flange (33) coupled to the syringe body (34), as shown. Fig. 9B At this point, the mixing configuration latch (300) radially extends from the plunger assembly (44), thereby preventing the plunger assembly (44) from moving proximally relative to the syringe body (34).

[0083] Preventing proximal movement of the plunger assembly (44) allows the user to release pressure on the plunger actuation interface (128) when the liquid first drug component is forced from the proximal drug chamber (40) into the distal drug chamber (42) without allowing the plunger assembly (44) to be driven proximally by pressure accumulated in the distal drug chamber (42).

[0084] The radial extension of the mixing configuration latch (300) after being radially compressed by the tapered portion past the detent (302) produces an audible or tactile signal (i.e., a click). The audible or tactile signal indicates to the user that the dual chamber safety syringe system is in the mixing configuration and the user can release the pressure on the plunger operation interface (128). The user can also stir and / or flip the dual chamber safety syringe system to mix the drug components (252, 254) after hearing or feeling the audible or tactile signal.

[0085] C. Mixed Configuration Indicator

[0086] Fig. 10A and 10B Depicts the system in the transport configuration ( Fig. 10A ) and mixed configurations ( Fig. 10B ) Figures 6A-9B The portion of the dual chamber safety injection system shown in FIG. 1 includes proximal and distal stop members ( 32 , 36 ). Fig. 10A and 10B , showing that the proximal drug chamber (40) in the system in the delivery configuration is contracted when the system moves to the mixing configuration. As described above, the liquid first drug component (252) in the proximal drug chamber (40) in the system in the delivery configuration is transferred to the distal drug chamber (42) via at least one proximal opening (270), the transfer tube (46) and the intermediate opening (266).

[0087] For optimal performance, the pressure applied by the user to the plunger control interface (128) to cause the proximal stop member (32) to move distally relative to the distal stop member (36) should not exceed the pressure required to transfer liquid through the transfer tube (46) at a maximum rate (the "maximum transfer pressure"). The maximum transfer pressure is determined by various system parameters, including but not limited to the cross-sectional area and length of the transfer tube and the viscosity of the liquid. If the applied pressure exceeds the maximum transfer pressure, the remaining incompressible liquid in the proximal drug chamber (40) transmits the applied pressure to the distal stop member (36), thereby causing the distal stop member (36) to move distally relative to the syringe body (34) and the needle spine assembly (76) connected thereto.

[0088] Moving the distal stop member (36) relative to the needle spine assembly (76) before reaching the mixing configuration may prematurely stop the liquid transfer by moving the distal stop member (36) over the intermediate opening (266) before all of the liquid in the proximal drug chamber (40) is transferred to the distal drug chamber (42). Because the lumen plug (268) prevents liquid from traveling from the proximal opening and the intermediate opening (270, 266) to the distal opening (264), closing the intermediate opening (266) with the distal stop member (36) effectively stops the liquid transfer before it is completed. With more pressure applied, the distal stop member (36) can move more distally, thereby placing the intermediate opening (266) in the proximal drug chamber (40) before the liquid transfer is completed. This also stops the liquid transfer before it is completed. Therefore, applying a pressure greater than the maximum transfer pressure will result in incomplete liquid transfer, which will affect the dissolution of the substantially non-liquid second drug component (254), and / or the concentration of the mixed drug solution (272).

[0089] To solve the problem of users applying more pressure than the maximum transfer pressure, Fig. 10A and 10B The illustrated embodiment includes a mixing configuration indicator (304), which is a visual indicator disposed on the syringe body (34). Fig. 10A and 10BThe mixing configuration indicator (304) in is a ring disposed (e.g., painted, etched, etc.) on the syringe body (34) that indicates the approximate optimal position of the distal edge of the distal stop member (36) when the system is in the mixing configuration. This visual indicator / prompt allows the user to visually detect when the distal stop member (36) has moved too far distally relative to the syringe body (34) before the system reaches its mixing configuration. When the user detects such movement, the user can reduce the pressure applied to the plunger operating interface (128) to stop / slow the distal movement of the distal stop member (36). In some embodiments, an audible or tactile signal from the mixing configuration latch (300) indicates to the system when the system has reached the mixing configuration and it is safe to push the distal stop member (36) distally past the mixing configuration indicator (304).

[0090] A dual chamber safety injection system with a mixing configuration indicator (304) may include directions for use that instruct the user to "DO NOT ALLOW THE FRONT / DISTAL STOP TO GO BEYOND THE MIXING LINE UNTIL YOU HEAR A CLOTTE." The mixing configuration indicator (304) allows the user to vary the pressure applied to allow the system to transfer liquid with minimal movement of the distal stop member (36). The mixing configuration indicator (304) may eliminate the need for various friction-increasing features previously used to control stopper movement during the liquid transfer phase of the mixing process.

[0091] D. Distal Stop Bushing and Proximal Stop Thread

[0092] Figures 11A-11E Shown in increased detail Figure 6A-10B The dual chamber safety injection system is shown to demonstrate the various features of the system. Fig.11E As best shown in FIG. 1 , while the proximal and distal stop members ( 32 , 36 ) are activated as conventional off-the-shelf stops for an injection system, each of the proximal and distal stop members ( 32 , 36 ) is modified using additional components to optimize the performance of the dual chamber safety injection system.

[0093] Fig.11EThe distal stop member (36) is shown disposed in the syringe body (34) in an orientation opposite to the typical orientation of the stopper. In the opposite orientation, the lubricating coating (308) on the distal stop member (36) faces the proximal medicament chamber (40), and the internal threads on the inner surface of the distal stop member (36) face the distal medicament chamber (42). On the other hand, the proximal stop member (32) is disposed in the syringe body (34) in a typical orientation so that its lubricating coating (306) faces the proximal medicament chamber (40), and its internal threads face the plunger assembly (44). The corresponding internal threads of the proximal stop member and the distal stop member (32, 36) are configured for attachment. Typically, the internal threads are used to attach the plunger assembly. However, the dual chamber safety injection system described herein utilizes internal threads to attach additional components to optimize performance. The lubricious coating (306, 308) may be PTFE that acts as a fluid barrier to protect (eg, butyl rubber) the proximal and distal stop members (32, 36) from the first medicament component (40) in the proximal medicament chamber, or vice versa.

[0094] The distal stop bushing (310) is secured to the distal stop member (36) using the interaction between the external threads (312) on the distal stop bushing (310) and the distally facing internal threads on the distal stop member (36). Figures 12A-12D are shown separately. Fig.11E and 12D As shown, the distal stopper bushing (310) defines an alignment funnel (314) that faces distally when the distal stopper bushing (310) is installed in the distal stopper member (36), which is in turn installed in the dual chamber safety injection system. The distally facing alignment funnel (314) is configured to guide the needle proximal end (50) into position when the dual chamber safety injection system is assembled. Fig.11E and 12DAs shown, the distal stopper bushing (310) also defines a receiving space (316) configured to receive the needle proximal end (50) when the dual chamber safety injection system is assembled in a delivery configuration. The receiving space (316) is located near the "piercing" section of the rubber distal stopper bushing (310), which is configured to be pierced by the needle proximal end (50) to expose at least one proximal opening (270) leading to the proximal drug chamber (40) to allow liquid transfer. During assembly, the distally facing alignment funnel (314) guides the needle proximal end (50) into the receiving space (316), which secures the needle proximal end (50) during delivery and storage of the dual chamber safety injection system. The alignment funnel (314) also guides the needle proximal end (50) during liquid transfer and / or needle retraction to ensure that the needle proximal end (50) enters the plunger rod funnel for needle retraction (as described in U.S. Patent Application Serial No. 62 / 416,102, which is incorporated herein by reference above). The distal stopper bushing (310) also defines a bushing flange (318) that seals against a distal-facing surface of the distal stop member (36) to limit contact between the second drug component in the distal drug chamber (42) and the distal stop member (36) during transport and storage of the dual chamber safety injection system. The bushing flange (318) also prevents liquid from leaking under pressure between the distal stopper bushing (310) and the distal stop member (36). In an alternative embodiment, the distal stop bushing (310) and the distal stop member (36) are integrated into one solid rubber stop member with the "penetration" section and funnel geometry molded in. A lubricious coating may be applied to the distal, proximal, and / or circumferential sides of the distal stop member (36) and / or alignment funnel (314).

[0095] Fig.12E and 12F A guide disc (320) according to another embodiment is depicted having similar features to the distal stop bushing (310) described above. The guide disc (320) further defines an alignment funnel (314') that tapers proximally downward to a receiving space (316'). The guide disc (320) further defines a radial spring arm (321) that engages the inner surface of the syringe body (34) to center the guide disc (320) and guide the proximal end of the needle (50) into the plunger rod assembly (44) for needle unlocking and / or retraction during piercing of the distal stop member (36) (as described in U.S. patent application Ser. No. 62 / 416,102, which has been incorporated herein by reference previously). Fig.12E As shown, guide plate (320) may be used with distal stop member (36') mounted in a conventional manner (ie, facing distally).

[0096] The proximal stopper screw (322) is secured to the proximal stopper member (32) using the interaction between the external threads (324) on the proximal stopper screw (322) and the proximally facing internal threads on the proximal stopper member (32). Figures 13A-13C are shown separately. Fig.11E and 13C As shown, the proximal stopper thread (322) defines an alignment funnel (326) and a sealed space (328). The length of the sealed space (328) is greater than or equal to the distance between the proximal opening (270) and the middle opening (266) (see Figure 6N and 6O ).

[0097] After the needle proximal end (50) has pierced both the distal stop member and the proximal stop member (36, 32), the alignment funnel (326) is configured to guide the needle proximal end (50) into the sealed space (328). During the early injection stage, the intermediate opening (266) is retained in the distal drug chamber (42), thereby providing a fluid path through the transfer tube (46) into the plunger assembly (44). The sealed space (328) of the proximal stopper thread (322) is configured to prevent liquid (e.g., mixed drug solution (272)) from traveling retrograde in the intermediate opening (266) through the transfer tube (46) and out of the proximal opening (270). The proximal stopper thread (322) has a proximal septum (330) that maintains the seal to prevent retrograde liquid travel until the intermediate opening (266) is disposed in and sealed by the proximal stopper thread (322). The proximal stopper thread (322) may be made of a rigid plastic portion including external threads (324) and a rubber or elastomeric portion defining an alignment funnel (326) and a sealing space (328), and includes a proximal septum (330).

[0098] Exemplary Dual Chamber Safety Cartridge System

[0099] Fig.14A and 14BA similarly sized cartridge (134) and syringe body (34) are depicted separately. Both the cartridge (134) and the syringe body (34) can be made of glass. While the syringe body (34) is configured for use in an injection system, the cartridge (134) is configured for storing a substance (e.g., a drug). This results in several differences between the cartridge (134) and the syringe body (34). For example, while the proximal end of the syringe body (34) includes a conventional integral syringe flange (38), the proximal end of the cartridge (134) does not include an integral flange. Furthermore, while the distal end of the syringe body (34) includes a Luer taper configured to allow a snap-fit ​​engagement of a needle coupling assembly (606), the distal end of the cartridge (134) includes a flange (102) configured for securing a conventional cartridge seal (not shown). A conventional cartridge seal includes an elastically compressible seal that is at least partially surrounded by an elastically deformable closure member (e.g., an aluminum ring). As shown in FIG. Fig.14A and 14B As shown, the distal opening of the cartridge (134) is significantly larger than the corresponding distal opening of the syringe body (34). This provides more airflow for lyophilization as described above.

[0100] Fig. 14C and 14D Depicted is a dual chamber safety injection system built around a cartridge (134) rather than a syringe body (34). Replacement of the syringe body (34) with the cartridge (134) results in two changes to the dual chamber safety injection system. The first change is that the small diameter flange (33) is glued or press-fitted onto the cartridge (134) rather than coupled to the syringe flange.

[0101] A second difference in the dual chamber safety injection system built around the cartridge (134) involves coupling the needle coupling assembly (606) to the distal end of the cartridge (134), such as Figures 14C-16H As shown. Fig.14E As shown, the needle coupling assembly (606) is coupled to the distal end of the cartridge (134) using a collet / coil (104) and a sleeve (106). The collet (104) may be welded to the base plate of the needle coupling assembly (606). Fig.15A and 15B The system assembly step is shown wherein the needle distal portion (50) of the needle coupling assembly (606) is inserted into the distal drug chamber (42). Fig. 15B and 15D As shown, the collet (104) can expand to partially pass proximally over the flange (102) on the distal end of the cartridge (134). Fig.15D and 15EAs shown, after the proximal end (108) of the collet (104) has passed proximally of the flange (102), the sleeve (106) can be slid proximally over the collet (104) to prevent the collet (104) from opening and releasing from the flange (102). Securing the sleeve (106) over the collet (104) on the flange (102) secures the needle coupling assembly (606) to the distal end of the cartridge (134).

[0102] Figures 16A-16C The attachment of coupling assembly (606) to the distal end of cartridge (134) is again shown. Fig.16A and 16B The proximal needle end (50) is also depicted, showing that the alignment funnel (314) on the distal stopper hub (310) guides the proximal needle end (50) into the receiving space (316) during assembly of the dual chamber safety injection system. Fig.16D The attachment of the small diameter flange (33) to the proximal end of the cartridge (134) is shown, and the insertion of the plunger assembly (44) and the proximal stop member (32) secures it to the cartridge (134). Fig.16D The dual chamber safety injection system of the cartridge (134) shown is used in conjunction with Figures 7A-7P The dual chamber safety injection system with syringe is ready for delivery, storage and use (i.e., mixing, injection and automatic retraction) after the steps depicted are exactly the same.

[0103] Figure 16G and 16H Describes in detail the absence of ( Figure 16G ) and there are ( Fig.16H ) sleeve (106) in both cases the interface between the chuck (104) and the flange (102). Figure 16G and 16H Also depicted is a needle seal (110) disposed in the needle coupling assembly (606) and configured to fluidly seal an annular space between the inner diameter of the opening in the distal end of the cartridge (134) and the outer diameter of the needle spine assembly (76). The needle seal (110) may be made of an elastically deformable material such as rubber. The needle seal (110) also includes a pair of sealing rings (112) extending into the inner diameter of the needle seal (110). The sealing rings (112) function similarly to two O-rings that seal against the needle spine assembly (76).

[0104] The various features of the dual chamber safety injection system built around the cartridge (134) can also be used with autoinjectors or pen injectors. The cartridges of these systems can also incorporate an integral glass or plastic finger flange similar to that employed by syringe-based systems.

[0105] Exemplary Dual Chamber Safety Injection System with Luer Connector

[0106] Figures 17A-19D Various dual chamber safety injection systems are depicted having a Luer connector (114) at their distal ends. For use with a cartridge (134), such as Figures 17A-17H As shown, a female Luer lock connector (114) having internal threads is attached to a connector similar to Figures 14A-16H The collet (104) and sleeve (106) as shown and described above are connected to form a needle hub (116). The collet (104) and sleeve (106) can be used to connect the needle hub (116) to the distal end of the cartridge (134) as described above to attach the needle coupling assembly (606) to the Figures 14A-16H The distal end of the female Luer lock connector (114) is temporarily sealed with a removable Luer cap (118). Once the needle hub (116) is attached to the cartridge (134), the Luer cap (118) can be removed and the female Luer lock connector (114) can be used to attach the Luer needle (120) to the needle hub (116) and the dual chamber safety injection system, such as Fig.17E shown.

[0107] After the Luer needle (120) is attached to the needle hub (116) and the dual chamber safety injection system, the system is Figures 7A-7P The dual chamber safety injection system with syringe is ready for delivery, storage and use (i.e., mixing, injection and automatic retraction) following the exact same steps as depicted in FIG. Figures 17A-17H A dual chamber safety injection system with a female Luer lock connector (114) is depicted in Figures 7A-7P Mixing, injection, and retraction steps shown.

[0108] The use of a female Luer lock connector (114) and a replaceable Luer needle (120) introduces an additional complexity. The proximal end (122) of the Luer needle (120) must be connected to the delivery tube (46) while the Luer needle (120) is connected to the female Luer lock connector (114) on the needle hub (116). During the attachment of the Luer needle (120), the needle cover member (63) is configured to introduce the Luer needle (120) into the needle hub (116) so that the proximal end (122) of the Luer needle (120) is aligned with the delivery tube (46) to improve the connection between the Luer needle (120) and the delivery tube (46). The guide needle cover member is described in U.S. Patent Application Serial No. 14 / 696,342, which has been previously incorporated herein by reference. Figures 17J-17K18C-18F show the connection between the Luer needle (120) and the delivery tube (46). As shown in these figures, the male Luer lock connector (124) with external threads on the Luer needle (120) introduces the proximal end (122) of the Luer needle (120) into the delivery tube (46) for a secure connection therebetween. The threads on the Luer lock connector (114, 124) force the proximal end (122) of the Luer needle (120) into the delivery tube (46) for a sealed press fit or snap fit. The distal end of the delivery tube (46) also includes a latch groove (111), which is configured to interact with one or more cantilever latch members (616) to prevent the delivery tube from being pressed proximally into the cartridge (134) during the attachment of the Luer needle (120), as described below.

[0109] Figures 19A-19D An embodiment is shown in which a dual chamber safety injection system having a female Luer lock connector (114) at its distal end is used for mixing (with or without a Luer cap (118)) and injection without a Luer needle. The connector (114) can also be a Luer taper or Luer slip or other fluid connector. Fig.19D As shown, the dual chamber safety injection system can be connected to any Luer lock access port (130), such as the Luer lock access port connected to an IV tube and IV bag. In such an embodiment, the dual chamber safety injection system does not retract because no retraction mechanism is required due to the absence of a sharp needle. In this case, the transfer tube (46) can be stationary to allow liquid to be transferred from the proximal drug chamber (40) to the distal drug chamber (42), which then allows the mixed drug (272) to be injected into the IV tube or other injection system.

[0110] Although Figures 17A-19D The dual chamber safety injection system with the luer connector embodiment shown relates to a cartridge, but the luer connector may also be used with syringes and other dual chamber safety injection systems.

[0111] Exemplary safe injection system for metal-sensitive drugs

[0112] An increasing number of injectables, such as drugs, are sensitive to degradation during storage due to contact with metals, such as those present in needles. Figures 20A-20D The use of a pre-filled dual chamber safety injection system is depicted to minimize exposure of these sensitive drugs to metals during storage. For example, the sensitive drug (132) can be pre-filled in the system and stored in the proximal drug chamber (40), such as Fig. 20A, which depicts the delivery configuration of the dual chamber safety injection system. Thus, the sensitive drug (132) is only exposed to the glass of the syringe body (34) and the hydrophilic coating or lubricious coating (e.g., PTFE) on the proximal and distal stop members (32, 36) during delivery and storage. The distal drug chamber (42) contains only the proximal needle end (50) and does not contain any injectables. In effect, the distal stop member (36) separates the sensitive drug (132) from the metal needle proximal end (50) to which it is sensitive.

[0113] Just before injection, the user applies pressure to the plunger actuation interface (128), thereby pushing the proximal and distal stop members (32, 36) and the sensitive drug (132) contained therein distally. The needle proximal end (50) is configured such that, when the distal stop member (36) is positioned at the distal end of the syringe body (34), it has a single opening just proximal to the distal stop member (36), such as Fig. 20B Thus, the dual chamber safety injection system is ready for injection, as shown. Fig. 20B As shown. Fig. 20B In the configuration shown, further pressure applied by the user to the plunger operating interface (128) injects the sensitive drug (132) through the distal end (48) of the needle and causes the proximal drug chamber (42) to collapse, as shown in FIG. Fig. 20C As shown. Fig. 20C Go to Fig.20D , the needle spine assembly (76) is retracted into the syringe body (34) and at least partially retracted into the plunger assembly (44), as described in U.S. Patent Application Serial Nos. 14 / 696,342 and 62 / 416,102, which have been previously incorporated herein by reference. Thus, the time that the sensitive drug (132) is exposed to the metal of the needle spine assembly (76) is minimized to minimize the time it takes to complete the injection.

[0114] Although Figures 20A-20D The dual chamber safety injection system shown is configured for use with a syringe, but similar systems can be configured for use with cartridges containing sensitive drugs. Figures 20A-20D The dual chamber safety injection system shown involves direct injection from the proximal drug chamber (40), but other systems may involve movement of the sensitive drug from the proximal drug chamber (40) to the distal drug chamber (42) prior to injection, such as Figures 22A-22D shown.

[0115] Needle latch member

[0116] Figures 21A-21DDepicted is the interaction between the latch groove (111) on the distal end of the transfer tube (46) and the needle latch member (612) to prevent proximal movement of the needle spine assembly (76) (including the transfer tube (46)) prior to completion of an injection.

[0117] Fig.21A A transfer tube (46) is shown having a latch groove (111) formed therein and into which the proximal end of the distal needle end (48) is inserted. In one embodiment, the proximal end of the distal needle end (48) can be the proximal end of a Luer needle, as described above. The transfer tube (46) has a necked or radially reduced latch groove (111) that is configured to interface with the latch member (612) and the movable block member (614) so ​​that during system assembly and use (e.g., mixing and injection), the needle spine assembly (76) including the transfer tube (46) remains fixed in place relative to the syringe body (34), but the plunger assembly is not moved relative to the small diameter flange (33 - see e.g., Figure 7N ) is fully inserted (i.e., after the medicament that may be contained in the distal medicament chamber 42 of the syringe body 34 is nearly completely expelled or completely expelled), the needle spine assembly (76) is urged distally due to the advancement of the plunger, thereby advancing the movable block member (614) relative to the distal housing portion (610), so that the plurality of (two are shown) cantilevered latch members (616) of the latch member (612) are pushed open by the movable block member (614) to allow the needle spine assembly (76) (i.e., the needle distal end (48), the transfer tube (46), and the proximal end (50)) to be retracted, thereby safely placing the needle distal end (48) within the plunger assembly (44). Alternatively, the needle distal end (48) can be retracted to a position below the outer surface of the distal housing portion (610) to safely isolate the sharp point from the user. In other words, the cantilevered latch member (616) maintains the position of the needle distal end (48) during injection and needle / syringe assembly until they are pushed out of the way by the movable block member (614) when the plunger is fully inserted (see Fig.21D ), after which the needle can be freely withdrawn as described in U.S. patent application serial numbers 14 / 696,342 and 62 / 416,102, which have been previously incorporated herein by reference.

[0118] The movable block member (614) includes a smaller distal portion (617) and a larger proximal portion (618) to increase the force required to unlock the needle spine assembly (76). The larger proximal portion (618) is configured to form a block outer diameter (622) size that will interfere with the inner diameter (624) of the latch (612) to increase the force to slide the movable block, thereby increasing the force to unlock the needle.

[0119] The torque applied to the cantilevered latch member (616) is reduced, thereby increasing the force required to unlock.

[0120] Vacuum-assisted dual-chamber safety injection system

[0121] Figure 23-34 Describes something like Figure 6A-10B Various aspects of a vacuum-assisted dual-chamber safety injection system are shown. The dual-chamber safety injection system has a conventional off-the-shelf prefilled syringe body (34) in which a proximal stop member and a distal stop member (32, 36) are provided. The proximal stop member and the distal stop member (32, 36) together with the syringe body (34) define a proximal drug chamber and a distal drug chamber (40, 42). The proximal stop member and the distal stop member (32, 36) occlude the proximal and distal ends of the proximal drug chamber (40). The distal stop member (36) occludes the proximal end of the distal drug chamber (42). The dual-chamber safety injection system controls the transfer of a first drug component from the proximal drug chamber (40) to the distal drug chamber (42) and the exit of a mixed / combined drug from the distal drug chamber (42) which is subjected to a user inserting a plunger assembly in sequence at different degrees relative to the syringe body (34) at the distal end. The plunger assembly includes a proximal stop member (32), a plunger housing member (69) and a plunger manipulation interface (128). The first drug component located in the proximal drug chamber (40) can be a liquid, such as an aqueous or oily drug solution, a gel, or the first drug component can be a diluent for mixing with the second drug component in the distal drug chamber (42). The second drug component in the distal drug chamber (42) can be a drug in a dry form, such as a powder, microspheres, an emulsion, a lyophilized or freeze-dried drug, or a solid drug in the form of a cake. The second drug component in the distal drug chamber (42) can also be a liquid mixed with the first drug component from the proximal drug chamber (40).

[0122] As described above, the dual chamber safety injection system proximal and distal stop members (32, 36) are configured to be pierced by the proximal needle end (50) at the appropriate time to assist in drug transfer. Fig.23 The assembly is shown prior to use, with the needle cover (63) in place to mechanically isolate the distal needle end (48). The needle cover (63) can be removed and the assembly prepared for injection into a patient. In some embodiments (not shown), the needle cover member (63) includes a vent (not shown) for allowing pressure generated by the transfer and mixing of the drug components to escape from the interior of the syringe body (34) while preventing contaminants from entering the syringe body (34). However, such a vented needle cover member is not always desirable.

[0123] When the first drug component is transferred from the proximal drug chamber (40) to the distal drug chamber (42) under pressure without ventilation, pressure is built up in the distal drug chamber (42). The pressure accumulated in the distal drug chamber (42) can cause the liquid (e.g., mixed drug) to be expelled from the distal drug chamber (42) (e.g., through the needle distal end (48)) before injection.

[0124] therefore, Fig.23 The vacuum-assisted dual chamber safety injection system shown includes a partial vacuum (e.g., 0.1 ATM or 90% vacuum) in the distal medication chamber (42) prior to transferring the liquid from the proximal medication chamber (40). The partial vacuum facilitates the transfer of the liquid from the proximal medication chamber (40). For example, a portion of the transfer tube (46) is pushed past the proximal stop member (32) so that the proximal opening (270, see Fig.29 ) is disposed in the proximal medicament chamber (40), the partial vacuum in the distal medicament chamber (42) draws liquid from the proximal medicament chamber (40) into the distal medicament chamber (42). The partial vacuum reduces the amount of distally directed force that must be applied to the proximal stop member (32) via the plunger assembly to transfer liquid from the proximal medicament chamber (40) to the distal medicament chamber (42). Transferring the liquid also at least partially releases the vacuum in the distal medicament chamber (42).

[0125] like Fig.24 As shown, the partial vacuum in the distal medicament chamber (42) generates a force ("Fv") on the distal stop member (36) that must be temporarily resisted to maintain the dual chamber safety injection system in its delivery / storage / premixing configuration. The distally directed force (Fv) on the stop member (36) is approximately the difference between the pressure in the proximal medicament chamber (40) and the pressure in the distal medicament chamber (42) multiplied by the area of ​​the distal stop member (36). In one embodiment:

[0126] Pressure in proximal drug chamber (40) = 1 ATM (atmospheric pressure) = 14.7 psi (pounds per square inch)

[0127] Pressure in distal drug chamber (42) = 0.1 ATM = 0.15 psi

[0128] The area of ​​the distal side of a standard 3cc stopper = 0.09 in. 2

[0129] Force (Fv) on Distal Stop Member (36) = 0.09 (14.7-0.15) = 1.31 lbs. The resistance of the distal stop member (36) to piercing the harpoon-shaped coupling interface (not shown) may be sufficient to overcome the force (Fv) of 1.31 lbs. However, with a sharper harpoon-shaped coupling interface or a distal stop member (36) with less piercing resistance, the partial vacuum in the distal medication chamber (42) may cause the distal stop member (36) to be pierced prematurely by the harpoon-shaped coupling interface and even prematurely transfer liquid from the proximal medication chamber (40) to the distal medication chamber (42).

[0130] Fig.25 and 26 A distal stop bushing (310) is depicted, which includes a proximal door (332). The distal stop bushing (310) is configured to be screwed into the distal end of the distal stop member (36). The proximal door (332) includes a pair of movable arms (334) that are biased toward each other by corresponding spring elements (336). In this way, the proximal door (332) has two configurations: a closed configuration, in which the harpoon-shaped coupling interface cannot pass through the proximal door (332); and an open configuration, in which the harpoon-shaped coupling interface can pass through the proximal door (332). In the open configuration, the movable arms (334) are forced apart from each other (e.g., by relative movement of the harpoon-shaped coupling interface and the distal stop member (36) to open the door (332), as shown below).

[0131] When the dual chamber injection system is in the delivery / storage / premix configuration (see Fig.23 , 24 , 27 and 28), the door (332) is in a closed configuration. The closed door transmits the force (Fv) generated by the partial vacuum in the distal drug chamber (42) to the harpoon-shaped coupling interface and the needle spine assembly (76) without piercing the distal stop member (36) because the closed door (322) prevents the harpoon-shaped coupling interface from contacting the distal stop member (36), as shown in FIG. Fig. 27 and 28 As shown. The harpoon-shaped connection interface (89, see Fig.28 ) includes a proximal shoulder (90) that interferes with the closing door (322) to prevent the harpoon-shaped coupling interface (89) from passing therethrough. The harpoon-shaped coupling interface (89) has a hollow 3D arrow shape as described in U.S. Utility Patent Application filed on November 1, 2017 under attorney docket number CM.20015.00 and entitled “SYSTEM AND METHOD FOR SAFETY SYRINGE,” the disclosure of which has been previously incorporated herein by reference.

[0132] After a sufficient amount of distally directed force has been applied to the plunger assembly, the distally directed force applied to the plunger, together with the force (Fv) from the partial vacuum in the distal medication chamber (42) on the distal stop member (36), overcomes the bias of the spring element (336) in the arm (334) of the door (332) to move the door (332) from the closed configuration to the open configuration. Fig.29 As shown, the harpoon-shaped coupling interface (89) partially passes through the distal stop member (36), followed by the transfer tube (46). Since the outer diameter of the transfer tube (46) is smaller than the outer diameter of the distal end of the harpoon-shaped coupling interface (89), the door (332) closes after the proximal end of the harpoon-shaped coupling interface (89) passes therethrough.

[0133] Then, the movement of the needle spine assembly (76) through the distal stop member (36) is temporarily stopped by a distal shoulder (92) formed on the needle connection structure (83) on the needle spine assembly (76), the distal shoulder (92) having an outer diameter larger than the transfer tube (46). The distal shoulder (92) will not pass through the closed door (322), thereby keeping the needle spine assembly (76) and the distal stop member (36) in a closed position. Fig.29 The transfer tube (46) is in the position shown. In this position, the transfer tube (46) spans the distal stop member (36) and allows liquid to be transferred therethrough. The partial vacuum in the distal medication chamber (42) and the distally directed force applied to the plunger assembly pulls liquid from the proximal medication chamber (40) and pushes it to the distal medication chamber (42). The mechanical interference between the distal shoulder (92) and the closed door (322) minimizes movement of the distal stop member (36) during liquid transfer.

[0134] Fig.30 Depicted is the configuration of the dual chamber safety injection system after the transfer of fluid from the proximal medicament chamber (40) to the distal medicament chamber (42) is substantially complete. The proximal stop member (32) seals the harpoon-shaped coupling interface (89, see Fig.29 ) and transfer tube (46, see Fig.29 ) to stop the liquid transfer. The partial vacuum in the distal medication chamber (42) provides space in the distal medication chamber (42) after the liquid transfer to allow the user to mix the first and second medication components by agitating the components.

[0135] Fig.31 Depicted is a diagram of a plunger assembly that has been subjected to sufficient distal force to overcome the distal shoulder (92, see Fig.29 ) and closed door (322, see Fig.29 ) after mechanical interference between (ie, by opening the door (322)) the configuration of the dual chamber safety injection system. At the distal shoulder (92, see Fig.29 ) and closed doors (322, see Fig.29 ) no longer prevents the distal stop member and the proximal stop member (36, 32) from moving distally, the partial vacuum causes the space to collapse by causing the distal stop member and the proximal stop member (36, 32) to move distally. The distally directed force applied to the plunger assembly may also help collapse the space in the distal drug chamber (42) (compare Fig.30 and 31 ).

[0136] After the partial vacuum shrinks the space in the distal medication chamber (42), the distal medication chamber may include small bubbles that do not need to be purged prior to injection. Thus, unlike other injection systems, the vacuum-assisted dual-chamber safety injection system can operate without cleaning. Thus, the vacuum-assisted dual-chamber safety injection system described herein can be used with auto-injectors, injection pens, and other "reusable" or "disposable" housing interfaces without the need for cleaning.

[0137] Fig.32 The configuration of the dual chamber safety injection system is depicted after the needle latch member (612) has been disengaged from the needle spine assembly (76) and the harpoon coupling interface (89) has been secured to the needle retaining component as described above. For clarity, Fig.32 The energy storage components are omitted.

[0138] Fig.33 The configuration of the dual chamber safety injection system is depicted after the retraction mechanism has been triggered to retract the needle spine assembly (76) proximally relative to the syringe body (34) until the sharp end of the needle distal end is at least in a safe position in the needle hub as described above. For clarity, Fig.33 The energy storage components are omitted.

[0139] Fig.34 A distal stopper bushing (310) according to another embodiment is depicted that includes a proximal door (332). Fig.34 The distal stopper bushing (310) and Figure 25-28 The difference between the distal stopper bushing (310) in FIG. 1 is the design of the proximal door (332). Fig.34In the illustrated proximal door (332), when the distal shoulder (92) presses against the movable arms (334) in the proximal direction, the pair of movable arms (334) rotate about the respective self-energizing hinges (338). The force of the distal shoulder (92) on the movable arms (334) causes the arms to move closer to each other, thereby securing the transfer tube (46) to the movable arms (334). This secures the transfer tube (46) in an optimal position for liquid transfer. The position of the transfer tube (46) in a fixed position can be adjusted by varying the axial length of the self-energizing hinge (338) to adjust the force on the transfer tube (46) from the movable arms (334). After liquid transfer is complete, the distally directed force on the plunger assembly overcomes the mechanical interference between the distal shoulder (92) and the closed door (322) to allow injection.

[0140] Figure 23-33 The vacuum-assisted dual-chamber safety injection system shown and described herein facilitates the transfer of liquid from the proximal medication chamber (40) to the distal medication chamber (42) by drawing the liquid into the distal medication chamber (42) and by minimizing the pressure buildup in the distal medication chamber (42) due to the liquid transfer. The vacuum-assisted dual-chamber safety injection system also includes a distal stopper bushing (310) having a proximal door (332) to prevent premature movement of the distal stopper member (36) caused by a partial vacuum in the distal medication chamber (42).

[0141] Various exemplary embodiments of the present invention are described herein. These examples are described in a non-limiting sense. These examples are provided to more broadly illustrate the applicable aspects of the present invention. Various changes may be made to the described invention and may be substituted with equivalents without departing from the true spirit and scope of the present invention. In addition, many modifications may be made to make specific conditions, materials, components of matter, methods, method actions or steps compatible with the purpose, spirit or scope of the present invention. In addition, as will be appreciated by those skilled in the art, each individual variation described and illustrated herein has independent components and features, which may be easily separated or combined with the features of any other several embodiments without departing from the scope or spirit of the present invention. All such modifications are intended to fall within the scope of the claims associated with this disclosure.

[0142] Any of the devices described for performing the targeted diagnostic or interventional procedures may be provided in a packaged assembly for use in performing such interventions. These supply "kits" may also include instructions for use and be packaged in sterile trays or containers as are commonly employed for such purposes.

[0143] The present invention includes methods that can be performed using target devices. These methods may include the step of providing such suitable devices. Such providing may be performed by the end user. In other words, the providing step only requires the end user to obtain, intervene, approach, locate, set, enable, power on and other actions to provide the necessary devices in the target method. The methods set forth herein may be performed in any logically feasible order of the events set forth and in the order of events described.

[0144] Exemplary aspects of the present invention and the details relevant to material selection and manufacture have been stated above. For other details of the present invention, it can be understood in conjunction with the patents and bulletins cited above and is generally known or understood by those skilled in the art. For example, it will be appreciated by those skilled in the art that one or more lubricating coatings (for example hydrophilic polymers such as synthetics based on polyvinyl pyrrolidone, fluoropolymers such as tetrafluoroethylene, hydrophilic gels or silicones) can be used in combination with the various parts of the device (if necessary, such as the larger tapping interface of the part that is movably connected), to for example facilitate the low friction manipulation or forward movement of such objects relative to other parts of the apparatus or nearby tissue structures. In terms of the additional steps as usually or logically adopted, the aspect based on the method of the present invention can have the same situation equally.

[0145] Furthermore, although the invention has been described with reference to several examples optionally incorporating various features, the invention is not limited to the features described or indicated as contemplated with respect to the various variations of the invention. Various modifications may be made to the invention and may be substituted with equivalents (whether stated herein or not included for reasons of brevity) without departing from the true spirit and scope of the invention. Furthermore, where a range of values ​​is provided, it is understood that each intervening value between the upper and lower limits of the range and any other exposition or intervening value within the exposition is included within the invention.

[0146] In addition, it is conceivable to state and claim any optional features of the variants of the invention described, either alone or in combination with any one or more of the features described herein. Reference to singular items includes the possibility of the presence of multiple identical items. More specifically, as used herein and in the claims associated therewith, the singular forms "one", "an", "said" and "the" include multiple referents unless specifically stated otherwise. In other words, the use of articles allows "at least one" of the target items in the above description and claims associated with the present invention. It should also be noted that such claims are written to exclude any optional elements. Therefore, this statement is intended to be used as a pre-conditional basis for the use of exclusive terms such as "solely", "only" and the like in conjunction with the recitation of claim elements or the use of "negative" limitations.

[0147] Without using such exclusive terms, the term "comprising" in the claims related to the present invention shall allow the inclusion of any additional elements, regardless of whether a certain number of elements are enumerated in such claims or the addition of features can be considered to transform the nature of the elements recited in such claims. Unless otherwise specifically defined herein, all technical and scientific terms used herein are provided with the broadest commonly understood meanings, provided that the validity of the claims is maintained.

[0148] The scope of the present invention is not limited to the examples provided and / or this description, but is only limited by the scope of the claims associated with this disclosure.

Claims

1. A system for mixing and injecting medicines, comprising: a tubular injection body defining a proximal opening and a distal needle hub at a distal end thereof; a proximal stopper and a distal stopper disposed in the tubular injection body to form a proximal medicament chamber between the proximal stopper and the distal stopper and a distal medicament chamber between the distal stopper and a distal end of the tubular injection body; A plunger member defining a plunger interior and configured to be inserted into a proximal stop relative to a tubular injection body, the plunger member comprising: a needle retaining feature disposed within the plunger, an energy storage member disposed within the plunger, and an energy storage member latch member disposed within the plunger; and A needle hub assembly coupled to a distal needle hub of a tubular injection body, the needle hub assembly comprising: A needle having a needle proximal feature structure, Seat, and a needle latch member configured to couple the needle to the hub, wherein the first and second sizes of the respective proximal and distal medicament chambers are changeable by movement of the proximal and distal stops relative to the tubular injection body, wherein the needle is at least partially retractable into the interior of the plunger upon insertion of the plunger member relative to the tubular injection body to transform the energy storage member latching member from a latched state to an unlocked state, and The distal stopper comprises a funnel arranged at its distal end, and the funnel tapers toward the proximal direction, so that the inner diameter of the distal end of the funnel is greater than the inner diameter of the proximal end of the funnel.

2. The system according to claim 1, wherein: The needle is configured to at least completely pierce the distal stopper to retract into the interior of the plunger.

3. The system according to claim 1, wherein: The proximal and distal medicament chambers contain first and second components, respectively, of a medicament to be mixed together prior to injection into a patient.

4. The system according to claim 1, wherein: The system has a delivery configuration wherein the needle proximal feature is disposed within the distal drug chamber, a transferred configuration wherein the needle proximal feature has at least partially pierced the distal stopper and is at least partially disposed within the proximal medicament chamber, and A mixing configuration wherein the proximal stopper and the distal stopper contact each other to transfer the first medicament component from the proximal medicament chamber to the distal medicament chamber to mix the first medicament component with the second medicament component in the distal medicament chamber.

5. The system according to claim 4, wherein: The needle comprises: Distal opening; a central opening disposed in the distal drug chamber when the system is in the delivery configuration, the transfer configuration, and the mixing configuration; and A proximal opening is disposed in the proximal medication chamber when the system is in the transfer configuration.

6. The system according to claim 5, wherein: The needle further comprises a plurality of proximal openings, the proximal opening being one of the plurality of proximal openings, wherein at least some of the plurality of proximal openings are disposed in the proximal medication chamber when the system is in the transfer configuration, and Wherein at least some of the plurality of proximal openings are configured to be occluded by a proximal stopper when the system is in the hybrid configuration.

7. The system according to claim 6, wherein: The proximal stopper includes a plug configured to occlude at least some of the plurality of proximal openings when the system is in the hybrid configuration.

8. The system according to claim 7, wherein: The length of the plug is greater than the distance between the most proximal opening of the plurality of proximal openings and the most distal opening of the plurality of proximal openings.

9. The system according to claim 4, wherein: The tubular injection body includes a position indicator configured to be adjacent to the distal end of the distal stop when the system is in the mixing configuration.

10. The system according to claim 4, wherein: The plunger member includes a retaining clip configured to selectively couple to the tubular injection body to prevent proximal movement of the plunger member relative to the tubular injection body when the system is in the mixing configuration.

11. The system according to claim 10, wherein: The retaining clip is configured to generate an audible signal when the retaining clip is selectively coupled to the tubular injection body.

12. The system of claim 1, wherein: The proximal stopper and the distal stopper respectively include corresponding opposing surfaces, the opposing surface of the proximal stopper faces distally, and the opposing surface of the distal stopper faces proximally, and the proximal stopper and the distal stopper include corresponding first polymer coatings and second polymer coatings on their corresponding opposing surfaces, so that the proximal drug chamber is defined by the tubular injection body and the first polymer coating and the second polymer coating.

13. The system of claim 1, wherein: The distal medication chamber contains a partial vacuum.

14. The system according to claim 13, wherein: The distal stopper includes a proximal door having a closed configuration in which the needle proximal end features cannot pass through the proximal door and an open configuration in which the needle proximal end features can pass through the proximal door.

15. The system of claim 14, wherein: The proximal door includes a pair of movable arms operably coupled to a pair of spring elements that bias the proximal door in a closed configuration.

16. The system of claim 14, wherein: The needle proximal end feature includes a proximal shoulder that is unable to pass through the proximal door in the closed configuration but is able to pass through the proximal door in the open configuration.

17. The system of claim 16, wherein: The needle includes a distal shoulder that is unable to pass through the proximal door in the closed configuration but is able to pass through the proximal door in the open configuration, and wherein the distal shoulder is distal to the proximal shoulder.

18. The system of claim 14, wherein: The proximal door includes a pair of movable arms operably coupled to a pair of self-energizing hinges.

19. The system of claim 1, wherein: The funnel is configured to receive the needle proximal feature and guide the needle into coaxial alignment with the distal stop.